Johnson & Johnson will resume the launch of the COVID-19 vaccine in Europe, the company announced Tuesday, with additional packaging labels warning of a rare risk of blood clots.
The announcement came after the European health regulator, the European Medicines Agency, said the benefits of the vaccine outweigh the risk of the rare and potentially fatal side effect.
The deployment of J&J vaccines in Europe was suspended after US regulators stopped using the company’s firing last week after it was reported that six women were suffering from blood clots.
“It simply came to our notice then. We hope to raise awareness, as well as establish a clear diagnostic and therapeutic direction, that can restore confidence in our vaccine, ”Paul Stoffels, scientific director of J&J, said during a conference on Tuesday.
Nearly eight million people in the U.S. have received the J&J vaccine.
The Centers for Disease Control and Prevention and Food and Drug Administration reviews the rare blood clots reported in people who received the shooting.
With publishing cables